Home GT Medical Technologies Inc.

GT Medical Technologies Inc.

GT Medical Technologies Announces FDA Clearance of Expanded Indication for GammaTile Therapy

Patients with newly diagnosed malignant brain tumors are now eligible to receive the FDA-cleared surgically targeted radiation therapy (STaRT).

University of Minnesota First in U.S. to Offer New Targeted Therapy for Recurrent Brain Tumors

2/14/19: “At University of Minnesota Health, our mission is to advance new, safe, and effective therapeutic options for the many brain tumor patients who did not respond to the standard-of-care therapies,” Chen said. “Moreover, the University of Minnesota Medical School’s Department of Neurosurgery has a long-standing history of contribution in radio-biologics. To be the first institution in the U.S. to offer the GammaTile Therapy is particularly satisfying in this context.”